1-4 of 4
Eliana B. Gomez
Close
Sort by
Journal Articles

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

Eliana B. Gomez, Kevin Ebata, Hetal S. Randeria, Mary S. Rosendahl, E. Peder Cedervall, Tony H. Morales, Lauren M. Hanson, Nicholas E. Brown, Xueqian Gong, Jennifer Stephens, Wenjuan Wu, Isabel Lippincott, Karin S. Ku, Richard A. Walgren, Paolo B. Abada, Joshua A. Ballard, Charles K. Allerston, Barbara J. Brandhuber
Journal: Blood
Blood (2023) 142 (1): 62–72.
https://doi.org/10.1182/blood.2022018674
Published: 2023
Includes: Supplemental data
Journal Articles

In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, Rituximab, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice

Eliana B. Gomez, PhD, Wenjuan Wu, PhD, Jennifer R Stephens, BS, Mary S. Rosendahl, PhD, Barbara J. Brandhuber, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-140581
Published: 2020
Journal Articles

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Aishath S Naeem, PhD, Winnie I Nguy, Svitlana Tyekucheva, PhD, Stacey M. Fernandes, BS, Vanessa Rai, BS, Kevin Ebata, PhD, Eliana B. Gomez, PhD, Barb J. Brandhuber, PhD, Stephen M. Rothenberg, MD PhD, Jennifer R Brown, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 478.
https://doi.org/10.1182/blood-2019-124362
Published: 2019
Journal Articles

Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations

Eliana B. Gomez, PhD, Lippincott Isabel, PhD, Mary S. Rosendahal, PhD, Stephen M. Rothenberg, MD PhD, Steven W. Andrews, PhD, Barb J. Brandhuber, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4644.
https://doi.org/10.1182/blood-2019-126114
Published: 2019